



Amedisys Presentation
J.P. Morgan Health Care Conference 2018

Forward-looking statements

This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as a prediction of future events.

Additional information regarding factors that could cause actual results to differ materially from those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, copies of which are available on the Amedisys internet website <http://www.amedisys.com> or by contacting the Amedisys Investor Relations department at (225) 292-2031.

We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law.

www.amedisys.com




NASDAQ: AMED

We encourage everyone to visit the Investors Section of our website at www.amedisys.com, where we have posted additional important information such as press releases, profiles concerning our business and clinical operations and control processes, and SEC filings.

The Home Health and Hospice Industries Continue to Grow

We continue to see steady growth in both Home Health and Hospice driven by favorable demographic trends, growing acceptance of each benefit and an increased recognition of our ability to drive cost out of higher cost settings while delivering high quality care

Enrollment in Medicare is Projected to Grow Rapidly in the Next 25 Years



Source: Medicare Payment Advisory Commission Reports to Congress – June 2017 data book
 Note: Enrollment numbers are based on Part A enrollment only. Beneficiaries enrolled only in Part B are not included
 *Share of all decedents = share of Medicare patients who passed away on Hospice

2018 Strategic Landscape

Amedisys is well positioned for success in 2018

LHCG & AFAM Merger of Equals



On November 16, 2017, LHC Group and Almost Family announced that they have agreed to combine in an all-stock merger of equals transaction:

- Almost Family shareholders will receive 0.9150 shares of LHC Group for each existing Almost Family share
- Upon closing, LHC shareholders will own 58.5% and Almost Family shareholders will own 41.5% of the combined company

HUM, TPG, WCAS Acquire KIND




On December 19, 2017, Kindred Healthcare announced its sale to TPG and Welsh Carson for \$9.00 per share, representing a ~\$4.1 billion transaction enterprise value

- Simultaneously with the acquisition by sponsors, Kindred at Home will be separated, and Humana will acquire a 40% stake in that business for \$800 million in cash


AMED Positioned for Growth

- Recent acquisition activity makes Amedisys one of only two publicly traded, pure-play, Home Health and Hospice companies of scale
- Our 2018 focus continues to be organic growth and inorganic expansion in all three lines of business
- The Home Health and Hospice industries remain very fragmented with the combined market share of the top five players in each space amounting to less than 20%

Number of Home Health Agencies



Number of Hospice Agencies




- Strong capital position allows for both large and small inorganic opportunities
- We will remain focused on our four core strategic pillars:
 - Clinical Distinction
 - Employer of Choice
 - Operational Excellence and Efficiency
 - Driving Growth



What we Accomplished and Where we are Going


What we Accomplished	Where we are Going
<ol style="list-style-type: none"> 1. Realized the \$46M annualized savings we promised 2. Delivered on our goal of clinical distinction, reaching 4.21 stars average in the Jan 2018 HHC preview with 88% of our providers at 4+ Stars 3. Lowered BD vacancy rate to 1.1% at the end of 3Q'17 from 8.6% in April 2017 4. Grew Hospice ADC to ~7,000 at the end of 3Q'17 5. Signed three Personal Care acquisitions making Amedisys the largest provider of Personal Care services Mass. 6. Lowered voluntary turnover to ~22%, down from ~29% 	<ol style="list-style-type: none"> 1. Improving productivity via increased proficiency in HCHB, Productivity Staffing Tool and standardized scheduling processes 2. Home Health Reorg will be complete Feb 1st driving \$7M - \$9M in run-rate savings 3. Portfolio optimization – focusing on margin improvement in underperforming care centers 4. Enhanced leadership training to drive improvement in turnover, onboarding, scheduling, episode management and employee engagement 5. Continuation of Business Development staffing strategy 6. Opportunistic M&A and balance sheet optimization
<p style="text-align: center;">2017</p>	<p style="text-align: center;">2018</p>



How we're tracking (3Q'17)



Status	Category	Update	Ongoing Initiative
●	Quality ratings (Stars & VBP)	Amedisys maintains above a 4-Star average (4.21) in the Jan 2018 HHC preview with 88% of providers at 4+ Stars; focusing on readmission reduction; Hospice quality metrics initially released	<ul style="list-style-type: none"> Continued focus on driving down 30 and 60 day readmissions rates, key value proposition for Medicare and other payors
●	Clinical Initiatives & Readmissions	Create innovative industry-leading, clinical programs and define, develop and implement standardized care protocols at point of care. Heart program rolled out in Feb. 2017, COPD on-track	
●	BD Staffing / Turnover	We exited September with 770 BD FTE's and are on pace to reach our next target of 775 BD FTE's by 4Q'17; significantly slowed turnover of productive staff that was occurring in late 2016	<ul style="list-style-type: none"> Continued focus on retention through engagement and development opportunities. Increased emphasis on HH BD staffing and retention paying dividends
●	Clinical Staffing & Turnover	During the third quarter, we filled over 1,300 clinical positions, building capacity for planned volume growth	
●	HCHB 2.0	Re-training the field to become system "super-users" or drive more efficiencies and organizational standardization	<ul style="list-style-type: none"> Focus of 2H'17 has shifted to HCHB 2.0 training – proof will be in productivity gains Aside from disruptions to A/R from Florida ZPIC and Tenet acquisition, making progress on reducing DSO
●	Cost Initiatives / Margin	We will deliver the run rate savings opportunities of \$46M by 4Q'17; delivered on margin opportunity despite rate cuts (margin adjusted for rate cuts and Personal Care is ~12% in 3Q'17)	
●	Accounts Receivable	DSO remained steady at 40.7. DSO excluding impact of FL ZPIC and Tenet acquisition was 38.0. Expect to reduce DSO to more normalized levels by end of year	
●	Home Health	Same store episodic admissions ex. FL closures and hurricane up +3%. Same store total episodic volume growth +5% (admissions + recertifications) [ex. FL closures and hurricane]	<ul style="list-style-type: none"> Home Health has realized impact of new BD FTE's in 3Q'17 Targeting total episodic growth of 4-6% in 4Q (ex. Florida closures) Focusing M&A efforts on Hospice and Personal Care, while maintaining price discipline 2018 Home Health Final Rule did not include HHGM
●	Hospice	Hospice performance continues to be stellar. Same store Hospice admissions +7% and SS ADC growth +14%	
●	Personal Care	Billable hours/quarter: +37%. Highly efficient integration process. Realizing synergies from HomeStaff acquisition. Targeting additional acquisitions and efficiency as platform is built out	
●	M&A	Valuations remain high. Continue focus on Hospice, Personal Care and strategic Home Health acquisitions but will remain disciplined. Pipeline full	
●	Reimbursement	Impact of rate cut ~\$4M in 3Q'17, offset by \$2M due to patient acuity levels. 2018 reimbursement for AMED (1.4%), half of the impact is due to the expiration of the rural add on (0.7%)	



Our Key Areas of Focus

1



Organic Growth

- **Home Health:** Rebuild of BD staff continues. BD FTE ramp helped us achieve our 3Q total episodic admit growth (+3% ex FL closures and hurricane). On track to achieve 4Q total episodic admit growth rate (ex. FL closures) of 4-6%. Same store episodic volume growth +5%
- **Hospice:** Continued growth at high single / low double digit pace (Admissions +7%, ADC +14%)
- **Personal Care:** Double digit growth in billable hours / quarter +37%

2



BD Recruiting / Retention

- Focus on BD recruiting and retention payoff as BD FTEs at the end of Sept. at 770 projected to be 775 by 4Q'17 (increase of 58 FTEs vs. 4Q16)
- BD vacancy rate at end of September: 1.1%, down from 8.6% in April
- Targeting industry leading employee retention amongst all employee categories

3



Clinical Initiatives

- Amedisys improves STARS scores to 4.21 (Jan'18 preview) with 88% of providers at 4+ STAR rating
- STAR score improvement for the tenth consecutive quarter (from initial July'15 release to Jan'18 preview)
- 19 Amedisys providers (representing 29 care centers) rated at 5-Stars in the Jan'18 Preview
- Readmissions & clinical turnover
- Palliative care programs

4



Impact Capacity and Productivity

- Continued training on productivity tool optimization will help to impact RN / LPN & PT / PTA ratio and give field leaders better insight into capacity by clinician providing more clarity around staffing needs
- Since Jan. 1, 2017, clinician productivity has increased in the range of 5% (partially due to increased volume being available) – helping to drive down CPV

5



M&A

- Preference to acquire assets in: Hospice; Personal Care tuck-in's, and opportunistic regional acquisitions in Home Health
- Unlevered balance sheet (0.2x) gives us access to capital and lots of options
- Pipeline strong but price expectations challenging

6



Regulatory

- Home Health 2018 rule finalized on 11/1
- HHGM not included for implementation
- Working through details of final rule; final rule impacts AMED by (1.4%), half of this cut is due to rural add-on expiration
- 2018 Hospice rate increase of 1% effective 10/1/17
- Work with CMS on future payment reform

Highlights and Summary Financial Results (Adjusted): 3Q 2017⁽¹⁾



Same store Home Health Episodic admissions up (+3%) excluding Florida closures and hurricane impact. Hospice (+7% same store admissions) and Personal Care (+37% billable hours) continue their strong growth. Cost containment initiatives performing very well driving 3Q EBITDA, EPS and cash flows

3Q'17

Amedisys Consolidated

- Revenue Growth: +7%
- EBITDA: \$37M (+44%)
- EBITDA Margin: 9.5%
- EPS: \$0.56 (+56%)

3Q'17

Balance Sheet & Cash Flow

- Net debt: \$25.9
- Leverage ratio: 0.2x (net)
- CFFO: \$10.2M (\$38.9M ex. Legal Settlements)
- Free cash flow ⁽⁵⁾: \$8.3M (\$37.0M) ex. Legal Settlements

3Q'17

Home Health

Same Store Admissions ⁽²⁾:

- Episodic ⁽³⁾: +3%
- Non-Episodic: +3%

Same Store Volume ⁽⁴⁾:

- Episodic: +5%

Other Statistics:

- Total cost per visit: (1%)
- Recert Rate: +300 bps

3Q'17

Hospice

Same Store Volume:

- Admissions: +7%
- ADC: +14%

Other Statistics:

- Cost per day: (1%)

3Q'17

Personal Care

Growth Metrics ⁽⁶⁾:

- Billable hours/quarter: +37%
- Clients served: +14%

3Q'17

Adjusted Financial Results

\$ in Millions, except EPS	3Q16	3Q17
Home Health	268.9	276.0
Hospice	82.0	96.5
Personal Care	10.7	14.2
Total Revenue	\$ 361.6	\$ 386.7
Gross Margin %	41.3%	41.4%
Adjusted EBITDA	25.6	36.9
Adjusted EPS	7.1%	9.5%
Adjusted EPS	\$0.36	\$0.56
Free cash flow ⁽⁵⁾	\$3.9	\$8.3

1. The financial results for the three-month periods ended September 30, 2016 and September 30, 2017 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.
2. Same store admissions exclude 7 closed and consolidated care centers in FL and impact of hurricane.
3. Episodic admissions – Includes Medicare and non-Medicare payors that bill on a 60-day episode of care basis.
4. Same Store Episodic volume – Includes admissions and recertifications (ex. Florida closures and impact of hurricane).
5. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.
6. Includes acquisitions and full 3Q'16 impact of AHC (deal closed in March 2016).



Home Health and Hospice Segment (Adjusted) – 3Q 2017⁽¹⁾

Home health same store episodic volume up; Hospice continues to outperform

HOME HEALTH		
\$ in Millions	3Q16	3Q17
Medicare	203.9	197.9
Non-Medicare	65.0	78.1
Home Health Revenue	\$268.9	\$276.0
Gross Margin %	39.6%	39.1%
Segment EBITDA ⁽²⁾	31.9	33.2
	11.9%	12.0%

Operating Statistics		
Episodic admit growth - same store ⁽³⁾	3%	3%
Episodic admits - total	54,333	55,178
Episodic Recerts - total	28,376	31,006
Total Volume	82,709	86,184
Medicare admit growth - same store	1%	(3%)
Non-Medicare episodic admits - same store	19%	24%
Non-Medicare non-episodic admits - same store	(7%)	3%
Total Cost per visit	\$91.58	\$90.83

HOSPICE		
\$ in Millions	3Q16	3Q17
Medicare	77.0	91.4
Non-Medicare	5.0	5.1
Hospice Revenue	\$82.0	\$96.5
Gross Margin %	48.9%	50.5%
Segment EBITDA ⁽²⁾	21.3	28.5
	26.0%	29.5%

Operating Statistics		
Admit growth - same store	16%	7%
ADC growth - same store	14%	14%
Admits	5,751	6,257
ADC	6,087	7,026
Avg. discharge length of stay	92	95
Revenue per day (net)	\$146.49	\$149.25
Cost per day	\$74.77	\$73.99



Home Health Highlights

- Overall **same store episodic admissions** ex. FL closures and volume impact of hurricane +3%
- **Total same store episodic volume** growth +5% (admissions plus recertifications) [ex. Florida closures and hurricane]
- Expected **total episodic admissions growth** in 4Q (ex. FL closures): 4-6%
- Y/Y CPV decrease of (1%)



Hospice Highlights

- **Same store average daily census (ADC)** up 14%
- Net revenue per day up 2% y/y; gross margin expanded 160 basis points
- Cost per day down 1%; **segment EBITDA contribution up 13%**
- Only one provider over cap as of Q3'17, less than \$200k liability

1. The financial results for the three-month periods ended September 30, 2016 and September 30, 2017 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.
2. Segment EBITDA does not include any corporate G&A expenses.
3. Same store episodic admissions exclude 7 closed and consolidated care centers in FL and impact of hurricane.




General & Administrative Expenses – Adjusted ^(1,2)

Impact of G&A cost control materializing as operational efficiencies are realized

\$ in Millions	3Q16	4Q16	1Q17	2Q17	3Q17
Home Health Segment	70.7	67.4	68.0	68.0	68.1
Acquisitions - Tenet	-	-	-	0.9	1.2
Home Health Segment - Total	70.7	67.4	68.0	68.9	69.3
% of HH Revenue	26.3%	25.2%	25.1%	25.2%	25.1%
Hospice Segment	17.4	18.0	18.0	18.8	18.6
Acquisitions - Tenet	-	-	-	0.2	0.4
Hospice Segment - Total	17.4	18.0	18.0	19.0	19.0
% of HSP Revenue	21.2%	21.1%	21.0%	20.9%	19.7%
Personal Care Segment	2.2	2.9	3.3	3.0	3.0
% of PC Revenue	20.6%	22.8%	24.3%	20.8%	21.1%
Corporate Expenses	29.0	28.9	27.3	27.6	25.7
Acquisition Integration Costs	-	-	0.6	0.8	0.1
Total Corporate	29.0	28.9	27.9	28.4	25.8
% of Total Revenue	8.0%	7.9%	7.5%	7.5%	6.7%
Total	119.3	117.2	117.2	119.3	117.1
% of Total Revenue	33.0%	32.1%	31.6%	31.5%	30.3%

Corp G&A	3Q16	4Q16	1Q17	2Q17	3Q17
Salary and Benefits	13.8	13.7	13.9	14.1	13.6
Other	12.4	11.8	11.0	10.5	9.4
Corp. G&A Subtotal	26.2	25.5	24.9	24.6	23.0
Non-cash comp	2.8	3.4	2.4	3.0	2.7
Adjusted corporate G&A	29.0	28.9	27.3	27.6	25.7

Adjusted Corporate G&A (excl. Integration Costs)



Notes:

- **Year over year total G&A as a percentage of revenue decreased 270 basis points**
 - Home Health segment G&A: 120 bps y/y decrease as % of revenue
 - Hospice segment G&A: 150 bps decrease y/y as % of revenue
 - Personal Care segment G&A: 50 bps increase y/y as % of revenue
 - Corporate G&A: 130 bps decrease y/y as % of total revenue
- **G&A has decreased \$2.2M in 3Q17 vs. 3Q16**
- Home Health restructuring plan will further reduce G&A beginning in Q4'17



1. The financial results for the three-month periods ended September 30, 2016, December 31, 2016, March 31, 2017, June 30, 2017 and September 30, 2017 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.
2. Adjusted G&A expenses do not include bad debt expense or depreciation and amortization.

Our Stars scores have continued to trend upwards and are amongst industry leaders




Quality of Patient Care (QPC)*

Metric	APR 17 Release	OCT 17 Release	JAN 18 Preview
Quality of Patient Care	4.03	4.13	4.21
Entities at 4+ Stars	75%	81%	88%

Patient Satisfaction (PS)


Metric	Apr 17 Release	Jul 17 Release	OCT 17 Release
Patient Satisfaction Star	3.82	4.08	3.56*
Performance Over Industry	+5%	+8%	+6%

QPC Industry Performance



PS Industry Performance

*Scoring methodology changed dropped entire industry's PS STAR scores



Note: Top Competitor Avg weighted by CCN count and include LHC, Kindred, AFAM, HLS and BKD

- Amedisys maintains a 4-Star average in the Jan 2018 HHC release with **88% of our providers at 4+ Stars**
- **STAR score improvement for the eighth consecutive quarter** (from initial Jul 15 release to Jan 18 preview)**
- **Nineteen Amedisys providers (representing 29 care centers) rated at 5-Stars in the January 2018 preview**
- Industry impacted by calculation methodology change resulting in industry wide Patient Satisfaction drop



**JUL 17 and OCT 17 release periods use same OASIS data time frame. JUL 17 release excluded from this view to show improvement progression



On Target to Reach 775 BD FTEs by End of 4Q'17


Assuming a normalized level of BD productivity (~25 monthly admits / BD FTE) and meeting hiring and retention goals, we expect to achieve episodic growth of 4-6% for 4Q'17 excluding Florida closures

BD FTEs (2016 vs. 2017)

Dotted lines represent projections



BD Vacancy Rate




- Vacancy Rate goal of 6% by YE 2017 achieved and surpassed
- BD recruiting SWAT team responsible for the significant ramp in BD FTEs
- BD FTE impact will help us achieve 4-6% episodic growth in 4Q'17, excluding FL closures





\$46 million in Targeted Savings by Q4 2017

We are on track to realize the \$46M annualized savings we promised by Q4'17 – Additional Home Health restructure will put us over our original projections and help deliver improved margins despite reimbursement cuts

In early 2015, we discussed a plan to deliver \$46M in annualized run rate savings by the end of this year and have achieved much of this to date, which has driven improved margins



Unanticipated rate cuts in home health, a cumulative 3% as of Q3'17 have impacted margins. **Adjusting for these rate cuts and Personal Care, expected to deliver margins in the 12% range**






Operational Excellence: Cost Per Visit (CPV)

CPV decreased year-over-year despite planned salary increases, increased volume of visits has lowered our overall unit cost in several areas

Components	3Q'16	2Q'17	3Q'17	YoY Variance	Detail	Mitigation Plan
Salaries	\$62.34	\$60.34	\$61.65	(\$0.69)	YoY decrease driven by increased productivity. Sequential increase due to planned salary increases and impact of additional holiday	Staffing mix optimization, productivity and scheduling improvement initiatives in place helped us overcome planned salary increases
Contractors	\$2.61	\$2.58	\$2.81	\$0.20	Sequential increase due to slight increase in clinician turnover and increasing volumes	Contractor utilization decreases as clinician capacity increases post HCHB; increases due to increased volume in quarter
Benefits	\$10.94	\$10.83	\$11.12	\$0.18	Health insurance driving increase. Q3 and Q4 are the highest claim volume	Focus on cost containment and spend optimization
Transportation & Supplies	\$6.97	\$6.86	\$6.95	(\$0.02)	Sequential increase primarily due to supply costs	Initiatives underway including more effective medical supply contracting and optimized scheduling to reduce travel costs
*Visiting Staff CPV	\$82.86	\$80.61	\$82.53	(\$0.33)		
Clinical Managers	\$8.72	\$8.44	\$8.30	(\$0.42)	Fixed cost associated with non-visiting clinicians	Unit cost reduced as volume increases
Total CPV	\$91.58	\$89.05	\$90.83	(\$0.75)		

*Note: Direct comparison with industry competitors CPV calculation

Cost Per Visit (CPV)







Driving Top Line Growth: Metrics Across Business Segments

Solid growth in Hospice and Personal Care; Medicare episodic growth improving


Total Episodic Volume Growth (ex. Florida Closures and Hurricane)



Hospice Total Average Daily Census



Personal Care Total Hours / Quarter*



* Includes acquisitions - AMED closed AHC acquisition in March of 2016

Debt and Liquidity Metrics

Our debt levels remain very low (0.2x) providing us ample flexibility and available liquidity for strategic initiatives and inorganic growth opportunities

Outstanding Debt	As of: 09/30/17
Term Loan	91.3
Outstanding Revolver / Other Notes Payable	0.7
Total Debt Outstanding	92.0
Less: Deferred Finance Fees	(2.1)
Total Debt - Balance Sheet	89.9
Total Debt Outstanding	92.0
Less: Cash	(66.1)
Net Debt ⁽¹⁾	25.9
Leverage Ratio (net) ⁽²⁾	0.2

Credit Facility	As of: 09/30/17
Revolver Size	200.0
Outstanding Revolver	-
Letters of Credit	32.7
Available Revolver	167.3
Plus: Cash	66.1
Total Liquidity ⁽³⁾	233.4

Credit facility and cash provide significant capital for accretive acquisitions and/or other capital deployment options



1. Net debt defined as total debt outstanding (\$92M) less cash balance (\$66M).
2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA (\$136M).
3. Liquidity defined as the sum of cash balance and available revolving line of credit.

Adjusted EBITDA to Free Cash Flow Reconciliation ^(1,2)

Cash flow from operations impacted by Securities Class Action Lawsuit Settlement (net ~\$29M)

\$ in Millions	3Q16	4Q16	1Q17	2Q17	3Q17
GAAP Net Income	11.4	8.9	15.1	4.5	14.5
Taxes	6.7	5.6	9.9	(2.0)	9.4
Interest	1.1	1.6	1.1	1.1	1.3
Depreciation and amortization	5.2	5.0	4.4	4.5	4.2
Adjustments	1.2	9.4	1.5	28.0	7.5
Adjusted EBITDA	25.6	30.5	32.0	36.1	36.9
Provision for doubtful accounts	5.5	5.9	6.3	4.7	7.1
Non-cash compensation, includes 401(k) match expense	6.4	5.6	6.1	6.5	5.7
Cash taxes	-	-	(0.3)	-	-
Cash interest	(0.9)	(0.6)	(0.7)	(0.5)	(1.0)
Cash Adjustments	(1.8)	(4.9)	(1.9)	1.4	(18.5)
	34.8	36.5	41.5	48.2	30.2
Changes in working capital	(28.0)	(7.9)	(14.4)	(12.0)	(20.0)
Cash Flow from Operations	6.8	28.6	27.1	36.2	10.2
Capital expenditures - routine	(1.6)	(0.1)	(2.4)	(1.4)	(0.3)
Required debt repayments	(1.3)	(1.3)	(1.3)	(1.3)	(1.6)
Free cash flow	3.9	27.2	23.4	33.5	8.3
Capital Deployment					
Acquisitions	(3.7)	(4.1)	(4.1)	(20.0)	0.0
Share Repurchases	-	-	-	-	-
Total	(3.7)	(4.1)	(4.1)	(20.0)	0.0

1. The financial results for the three-month periods ended September 30, 2016, December 31, 2016, March 31, 2017, June 30, 2017 and September 30, 2017 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.
2. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.

Income Statement Adjustments ⁽¹⁾

Amount of non-GAAP adjustments, excluding Florida ZPIC audit and legal settlements, have substantially decreased. Trend to continue throughout 4Q'17.

\$oos	Income Statement Line Item	3Q16	4Q16	1Q17	2Q17	3Q17
Revenue						
Florida ZPIC audit	Revenue					6,506
Reduction of cost report reserve	Revenue		(1,149)			
Cost of Service						
Restructuring activity	Cost of service, excluding depreciation and amortization					101
G&A						
Acquisition costs	G&A, Salaries and benefits	101	56			
HCHB implementation	G&A, Salaries and benefits	56	15			
Restructuring activity	G&A, Salaries and benefits	2,044	3,340			2,474
Restructuring activity	G&A, Non-cash compensation	(493)	(1,481)			(905)
Restructuring activity	G&A, Other	414	16			
Data Center relocation	G&A, Other		101	714	226	
HCHB implementation	G&A, Other	1,937	1,330			
Acquisition costs	G&A, Other	366	820	682	294	
Legal fees - non-routine	G&A, Other	374	543	123	1,111	176
Securities Class Action Lawsuit settlement accrual, net	G&A, Other				28,712	
Frontier litigation	G&A, Other		2,479			
Wage and Hour litigation	G&A, Other		(119)			
Disaster relief	G&A, Other	339	129			
Sales/use tax audit reserve	G&A, Other		460			
Other Items						
Asset impairment	Asset impairment		4,432			
Legal settlements	Other, Miscellaneous, net	(1,242)	(280)	(674)	(693)	(647)
Sales/use tax audit reserve	Other, Miscellaneous, net		625			
Miscellaneous, other (income) expense, net	Other, Miscellaneous, net	(2,738)	(1,318)	621	(1,692)	(115)
Total		1,158	9,999	1,466	27,958	7,590
EPS Impact		\$0.02	\$0.18	\$0.03	\$0.49	\$0.13



1. The financial results for the three-month periods ended September 30, 2016, December 31, 2016, March 31, 2017, June 30, 2017 and September 30, 2017 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.